

### This week in techniques

| Approach  | Summary   | Licensing status   | Publication and contact information  |
|---|---|--|--|
| <b>Drug platforms</b>                                   |   |  |  |
| Mammalian cell-based antigen display screening platform | <p>A mammalian platform for surface antigen display could be used to screen for and discover therapeutic antibodies. A difficult step for <i>in vitro</i> antibody discovery is the cloning of candidates discovered via bacterial display systems into mammalian cell expression systems. In the current platform, human embryonic kidney 293 (HEK293) cells were transfected with a vector that caused them to display a protein on their surface and secrete it into culture media. The vector also was used to create HEK293 cell lines that displayed and secreted antibodies, antibody fragments and antibody fusion proteins. AnaptysBio Inc. has integrated this system into its SHM-XEL human antibody generation platform, and next steps include using the platform to develop therapeutic and diagnostic antibodies.</p> <p><b>SciBX 6(26); doi:10.1038/scibx.2013.672</b><br/> <b>Published online July 11, 2013</b></p> | Covered by issued and pending patents; antibody discovery platform already partnered with multiple companies and government agencies | <p>Horlick, R.A. <i>et al. J. Biol. Chem.</i>; published online May 20, 2013; doi:10.1074/jbc.M113.452482<br/> <b>Contact:</b> Robert A. Horlick, AnaptysBio Inc., San Diego, Calif.<br/>                     e-mail: <a href="mailto:rhorlick@anaptysbio.com">rhorlick@anaptysbio.com</a></p> |